Effect of Patient Cost Sharing on Treatment Discontinuation Among Rheumatoid Arthritis Patients

Bristol-Myers Squibb3,940 enrolled

Overview

The purpose of this study is to assess the impact of patient cost sharing on treatment discontinuation of biologic agents in patients with Rheumatoid Arthritis (RA)

Study Type

OBSERVATIONAL

Enrollment

3,940

Conditions

Rheumatoid Arthritis

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Patients diagnosed with Rheumatoid Arthritis (RA) who newly initiated a biologic DMARD (bDMARD) during a study timeframe of 1/01/06 to 3/31/09. Inclusion Criteria: * 18 to 64 years of age at index date * Diagnosis of RA during the study period (ICD-9CM 714.xx) * Evidence of at least one biologic DMARD of interest during the study timeframe * Continuous enrollment during the study timeframe * Both medical and pharmacy benefits * No evidence of a claim for a bDMARD in the 6-month pre-period Exclusion Criteria: * Patients are excluded if they have a diagnosis of psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, or ulcerative colitis at any time during the study timeframe; have a claim for Rituxan, IV etanercept, or IV adalimumab; or have Medicare or Medicaid during the study timeframe

Outcomes

Primary Outcomes

Effect of patient cost share on discontinuation

Time frame: Assessed from first prescription date and followed for 1-year

Secondary Outcomes

RA-related healthcare utilization and costs

Time frame: Pre-index: 6-month period prior to the index drug date

All-cause healthcare utilization and costs

Time frame: Pre-index: 6-month period prior to the index drug date

RA-related healthcare utilization and costs

Time frame: Post-period: Index date+365 days

All-cause healthcare utilization and costs

Time frame: Post-period: Index date+365 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.